PRISM ALS is a new global initiative designed to accelerate the discovery of effective treatments for ALS/MND by improving access to specially grown, patient-derived stem cell models that better reflect the biological diversity of the disease. The collaboration brings together ALS Therapy Development Institute (ALS TDI), LifeArc, and Axol Bioscience to develop high-quality iPSC-derived motor neuron models that can be used to test therapies, inform clinical trial design, and identify distinct biological subtypes of ALS/MND.

ALS TDI’s ALS Research Collaborative (ARC) Study is a remote research study that partners with people with ALS to collect longitudinal data about their disease. Participants contribute various information from home, including surveys and wearable sensor data. One important use of this data is to help researchers better understand how ALS progresses and how to measure that progression more precisely.

A letter from Zach Zangl, who was diagnosed with ALS in 2024 and now serves as a board member of ALS 100—a golf event that brings together elite players to complete 100 holes in a single day to raise awareness and fund ALS research.

Team Moira’s Ellie Smith on What Keeps Her Coming Back to the Tri-State Trek

PRISM ALS is a new global initiative designed to accelerate the discovery of effective treatments for ALS/MND by improving access to specially grown, patient-derived stem cell models that better reflect the biological diversity of the disease. The collaboration brings together ALS Therapy Development Institute (ALS TDI), LifeArc, and Axol Bioscience to develop high-quality iPSC-derived motor neuron models that can be used to test therapies, inform clinical trial design, and identify distinct biological subtypes of ALS/MND.

The ALS Therapy Development Institute (ALS TDI) is proud to announce that it will lead all research operations for Champion Insights—a new study planned to launch this fall in partnership with Answer ALS and Augie’s Quest to Cure ALS. This effort aims to uncover critical genetic and metabolic factors that may help explain the significantly higher incidence of amyotrophic lateral sclerosis (ALS) among endurance athletes, military service members, and other potentially high-risk groups.